Evaluation of the synergistic effect of coenzyme Q10 on contrast nephropathy

Phase 3

Recruiting

• Conditions: Condition 1: Contrast-induced nephropathy. Condition 2: chronic kidney disease.; Nephropathy induced by other drugs, medicaments and biological substances; Chronic kidney disease, unspecified; N 14.1; N18.9

• Registration Number: IRCT20220921056012N1
• Lead Sponsor: Rasht University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 February 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 210

Inclusion Criteria

GFR lower than 60
age upper than 18 years

Exclusion Criteria

perform urgent PCI or CAG before receiving standard care 24 hours before receiving contrast
presence of liver failure
presence of multiple myeloma disease and other plasma cell disorders
single kidney patients

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Contrast nephropathy that occurs if Cr increases and urine volume decreases less than 0.5 cc/kg/h for at least 6 hours will be considered equivalent to acute kidney injury. Timepoint: In both groups, at the beginning and on the third and fifth days, the baseline level of Bun-Cr-GFR and in addition the amount of urine volume will be measured on days 0 and 3. Method of measurement: Blood and urine laboratory tests to check Bun-Cr-GFR and urine volume.